A liquid biopsy is a non-invasive medical testing procedures that uses a sample of a patient's bodily fluids, such as blood, to detect and analyze cancer cells or genetic mutations associated with cancer.
The top companies operating in this vertical are-
In 2020, Qiagen acquired NeuMoDx Molecular, a Michigan-based molecular diagnostics company, for USD 248 million. This acquisition expanded Qiagen's portfolio of molecular diagnostic solutions, particularly in the area of infectious diseases.
With its headquarters in Venlo, Netherlands the company was established on November 29, 1984. It specializes in sample assay technologies for molecular diagnostics, pharmaceutical research, and applied testing, among others. It has also emerged as one of the leading companies in the development of liquid biopsy technologies. Its liquid biopsy solutions offer a non-invasive way to detect cancer and monitor treatment effectiveness through the analysis of circulating tumor DNA and RNA in bodily fluids like blood or urine
Qiagen envisions a future where healthcare is more precise and personalized through the use of molecular insights provided by their technologies.
In 2020, Adaptive Biotechnologies acquired Nodality, a biotech company that develops technologies to analyze cellular signalling pathways in cancer and immune cells.
Headquartered in Seattle, United States, the company was established in 2009. It specializes in the development of immune-driven therapies and diagnostic tests. The company uses next-generation sequencing (NGS) technology to decode the genetic information contained in immune cells.
Adaptive Biotechnologies’ primary vision is to leverage the power of the human immune system to diagnose and treat diseases more effectively.
In January 2022, ANGLE plc announced that it had received Breakthrough Device designation from the US FDA for its Parsortix system for use in the detection and monitoring of ovarian cancer. The designation is intended to accelerate the development and regulatory review of innovative medical devices.
The company was established in 1994 with its headquarters in the United Kingdom. It primarily develops liquid biopsy tests for cancer diagnosis and management. ANGLE plc's flagship product is the Parsortix system, which is a liquid biopsy platform that can capture and analyze circulating tumor cells (CTCs) from a simple blood test. The Parsortix system has the potential to enable earlier detection of cancer, monitor treatment response, and identify the emergence of resistance to therapy.
The company's vision is to revolutionize cancer care by providing non-invasive, highly accurate tests that can detect cancer at an early stage and guide treatment decisions.
In January 2022, Biocept announced that it had entered into a collaboration with a leading biopharmaceutical company to evaluate the use of its liquid biopsy technology in clinical trials for cancer drug development.
Established in 1997, the firm has its headquarters in San Diego, United States. It specializes in liquid biopsy tests for cancer diagnosis and treatment monitoring. The company has developed a Target Selector platform, which uses circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a simple blood sample to provide physicians with real-time information on a patient's cancer.
Biocept’s core mission is to leverage the power of liquid biopsy technology to provide physicians and patients with more accurate and timely information about cancer, ultimately leading to better treatment decisions and improved patient outcomes.
In 2021, Guardant Health acquired Bellwether Bio, a company that uses machine learning and liquid biopsy technology to detect early-stage cancers. The acquisition will enable Guardant Health to further expand its offerings in the early detection and treatment of cancer.
With is headquarters in Palo Alto, California, United States, the precision oncology company was established in 2011. It is primarily focused on developing and commercializing innovative blood-based tests for the early detection and management of cancer.
The company's vision is to transform cancer care through earlier detection and more accurate treatment. Guardant Health aims to provide patients and their physicians with the necessary tools to make informed treatment decisions and improve patient outcomes.
In June 2022, Epic Sciences generated a funding of USD 43 million in a Series F financing round led by Arsenal Capital Partners.
With its headquarters located in San Diego, United States, the company was established in the year 2008. It predominantly develops and commercializes blood-based tests to monitor and diagnose cancer.
The company's vision is to transform cancer care through the development of accurate, non-invasive diagnostic tests that enable earlier detection, more precise treatment selection, and better patient outcomes.
In July 2021, Sysmex announced the acquisition of a majority stake in HemoCell SAS, a French company that develops and produces innovative cell analysis systems for use in hematology and oncology.
With its headquarters in Kobe, Hogyo, Japan, the company was established on February 20, 1968. It specializes in the development and manufacture of diagnostic instruments, reagents, and software for medical institutions and clinical laboratories.
Sysmex Corporation's mission is to contribute to the advancement of healthcare by developing and providing innovative diagnostic and monitoring technologies that meet the needs of healthcare professionals and patients around the world.